English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs). The aim of this multicenter noninterventional study was to analyze treatment strategies and clinical effectiveness of these new options. Methods We set up a web-based registry on the science platform www.ClinicalSurveys.net and members of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO) were invited to provide clinical data on patients who received novel POS formulations. Data analysis was split into two groups of patients who received novel POS formulations for antifungal prophylaxis (posaconazole prophylaxis group) and antifungal therapy (posaconazole therapy group), respectively. Results One hundred eighty hospitalized patients (151 in the posaconazole prophylaxis group and 29 in the posaconazole therapy group) from six German tertiary care centers treated between July 2014 and March 2016 were included into our analysis. Seventy-six patients were female (42%) and median age was 58 years (range: 19 – 77 years). Most patients (n = 111; 62%) had an acute myeloid leukemia as primary underlying disease. In the posaconazole prophylaxis group and posaconazole therapy group, mean POS serum levels at steady-state were 1,154 µg/L (n = 40; 95% CI: 911 – 1,396 µg/L) and 1,097 µg/L (n = 19; 95% CI: 817 – 1,378 µg/L), respectively (P = 0.776). In the posaconazole prophylaxis group, nine (6%) probable/proven fungal breakthroughs were reported. In the posaconazole therapy group, 17 and 12 patients received POS as first-line therapy and salvage therapy, respectively. Most frequent indications were possible (n = 9) and probable (n = 7) aspergillosis and proven (n = 7) mucormycosis. The median overall duration of POS therapy was 18 days (IQR: 7–23 days). Thirteen patients (45%) had progressive IFD under treatment with novel POS formulations. Conclusion Our study demonstrates clinical effectiveness of antifungal prophylaxis with novel POS formulations. In patients treated for possible/probable/proven IFD, the observed tolerability and overall mortality was comparable to previous studies with other antifungals in similar patient population. Disclosures S. M. Heimann, MSD: Consultant, Grant Investigator and Lecture honoraria, Research grant and Speaker honorarium. W. J. Heinz, MSD: Grant Investigator and Speaker’s Bureau, Research grant and Speaker honorarium. J. Vehreschild, MSD: Grant Investigator and Speaker’s Bureau, Research grant and Speaker honorarium.

open forum infectious diseases

413. Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals